BioSpace News Archive

Adaptive Phage Therapeutics, Inc., today announced the first patient has been dosed in the PHAGE clinical trial, evaluating bacteriophage therapy in adults with cystic fibrosis (CF) who carry Pseudomonas aeruginosa ( P. aeruginosa ) in their lungs.

Unlearn®, the only artificial intelligence (AI) company developing prognostic digital twins to run smaller, faster clinical trials, today announced that Arman Sabbaghi, Ph.D. has been appointed Head of Biostatistics Research.

IMUNON, Inc., a clinical-stage drug development company announced it has received $1.6 million in net cash proceeds from the sale of approximately $1.7 million of its unused New Jersey net operating losses.

DiaCarta, Ltd. (“DiaCarta”) today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for its QuantiVirusTM MPXV test, which is a PCR test for the qualitative detection of DNA from monkeypox virus (MPXV) in lesion swabs collected from individuals suspected of monkeypox infection.

Evofem Biosciences, Inc. (OTCQB: EVFM) announced today that female telehealth leader Favor is now a specialty pharmacy provider of Phexxi® (lactic acid, citric acid and potassium bitartrate).

Evozyne today revealed a breakthrough AI model, developed in collaboration with NVIDIA, that the pharmaceutical industry can use to design therapeutic proteins.

Global health services company Cigna Corporation (NYSE:CI) will release its fourth quarter 2022 financial results on Friday, February 3, 2023, and will host a conference call the same day.

Today, Two Labs, an industry-leading pharma services company, is announcing the launch of its REMS strategy and program management offerings, which will be provided by its Shepherd Safety Services team.

TetraScience, the Scientific Data Cloud company, announced today that Labforward, a leader in optimizing laboratory workflows, has joined the Tetra Partner Network to enable scientists to maximize the value of their data utilizing the Tetra Scientific Data Cloud™.

RespireRx Pharmaceuticals Inc. is pleased to announce that, on January 11, 2023, it established ResolutionRx Ltd (“ResolutionRx”), a new, currently wholly-owned, unlisted public company in Australia.